Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

Journal of Clinical Psychiatry

Volumn 60, Issue 8, 1999, Pages 528-535

  Davidson, Jonathan R T ^a   DuPont, Robert L ^b   Hedges, Dawson ^c   Haskins, J Thomas ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Institute for Behavior and Health   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; PLACEBO; VENLAFAXINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; XEROSTOMIA;

EID: 0032869591     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0805     Document Type: Article

References (47)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:435-436
3. Kirkwood CK, Hayes PE. Anxiety disorders. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy. 3rd ed. Stamford, Conn: Appleton & Lange; 1991:1443-1462
4. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355-364
5. Zajecka J. Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry 1997;58(suppl 3):9-13
6. Flint AJ. Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 1994;151:640-649
7. Stoudemire A. Epidemiology and psychopharmacology of anxiety in medical patients. J Clin Psychiatry 1996;57(suppl 7):64-72
8. Hofmann SG, Barlow DH. The costs of anxiety disorders: implications for psychosocial interventions. In: Miller NE, Magruder KM, eds. Psychotherapy: Costs and Benefits. A Guide for Practitioners, Researchers and Policymakers. New York, NY: John Wiley & Sons. In press
9. DuPont RL, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety 1996;2:167-172
10. DuPont RL, DuPont CM, Rice DP. The economic costs of anxiety disorders. In: Stein DJ, Hollander E, eds. Textbook of Anxiety Disorders. Washington, DC: American Psychiatric Press. In press
11. Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry 1990;51(1, suppl):3-10
12. Roy-Byrne P, Wingerson D, Cowley D, et al. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am 1993;16:719-735
13. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-1405
14. Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol 1990;10: 101S-110S
15. Schweizer E, Rickels K. Strategies for treatment of generalized anxiety in the primary care setting. J Clin Psychiatry 1997;58(suppl 3):27-31
16. Buspirone HCI. In: Drug Facts and Comparisons. 1998 edition. St. Louis, Mo: Facts and Comparisons; 1998:1593-1596
17. Ninan PT, Cole JO, Yonkers KA. Nonbenzodiazepine anxiolytics. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1998:287-306
18. Buspirone hydrochloride. In: McEvoy GK, ed. AHFS 98 Drug Information. Bethesda, Md: American Society of Health-System Pharmacists; 1998:1960-1966
19. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50: 884-895
20. DuPont RL, DuPont CM. The treatment of anxiety: realistic expectations and risks posed by controlled substances. J Law Med Ethics 1994;22: 206-214
21. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-450
22. Hedges DW, Reimherr FW, Strong RE, et al. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996;32:671-676
23. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301
24. Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997;58(suppl 7):11-16
25. Wolfe RM. Antidepressant withdrawal reactions. Am Fam Physician 1997;56:455-462
26. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
27. National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985;21:839-843
28. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. Acta Psychiatr Scand 1983;67:361-370
29. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 1982;18:69-77
30. Raskin A, Schulterbrandt J, Reatig N, et al. Replication of factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives. J Nerv Ment Dis 1969;148:87-98
31. Spitzer RL, Williams JB, Gibbon M, et al. The structured clinical interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry 1992;49:624-629
32. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended-release (XR) in outpatients with major depression. J Clin Psychiatry 1997; 58:393-398
33. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294
34. Cunningham LA. Efficacy and tolerability of once daily venlafaxine extended release (XR) in outpatients with major depression. Ann Clin Psychiatry 1997;9:157-164
35. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
36. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998;18:136-144
37. Connor KM, Davidson JRT. The neurobiology of generalized anxiety disorder. Biol Psychiatry 1998;44:1284-1294
38. Grimsley SR. Anxiety disorders. In: Young LY, Koda-Kimble MA, Kradjan WA, et al, eds. Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver, British Columbia: Applied Therapeutics; 1995: 73-1-73-31
39. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended-release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62
40. Gray JA. A conceptual nervous system for avoidance behaviour. In: Gray JA, ed. The Psychology of Fear and Stress. 2nd ed. New York, NY: Cambridge University Press; 1991:241-271
41. Gray JA. Fear and the central nervous system. In: Gray JA, ed. The Psychology of Fear and Stress. 2nd ed. New York, NY: Cambridge University Press; 1991:272-330
42. Haskins T, Rudolph R, Pallay A, et al, for the Venlafaxine XR 210 Study Group. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD) [poster]. Presented at the 21st meeting of the Collegium Internationale Neuro-Psychopharmacologicum; July 12-16, 1998; Glasgow, Scotland
43. DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994;97(suppl 6A):13S-23S
44. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):37S-53S
45. Amchin J, Zarycranski W, Taylor KP, et al. Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 1998;34:211-219
46. Amchin J, Zarycranski W, Taylor KP, et al. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. J Clin Pharmacol 1999;39:252-259
47. Amchin J, Zarycranski W, Taylor KP, et al. Effect of venlafaxine on the pharmacokinetics of terfenadine. Psychopharmacol Bull 1998;34:383-389